Coeptis Therapeutics, Inc. (COEP) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
105 Bradford Road
Wexford, PA 15090
United States of America (the)
Phone
724 934 6467
Website
Sector
Healthcare
Industry
Biotechnology
Employees
5
First IPO Date
December 17, 2020
| Name | Title | Pay | Year Born |
| David Mehalick | Co-Founder, Chairman of the Board, Chief Executive Officer & President | 597,000 | 1969 |
| Christine Elise Sheehy | Co-Founder, VP of Compliance & Corporate Secretary | 75,000 | 1968 |
| Brian Cogley | Chief Financial Officer | 310,385 | 1987 |
| Daniel Alexander Yerace | Co-Founder, Vice President of Operations & Director | 452,000 | 1983 |
Coeptis Therapeutics, Inc. is a biopharmaceutical company dedicated to the advancement and market introduction of both generic and proprietary pharmaceutical products, as well as cell therapy platforms, specifically for individuals battling cancer. Their current portfolio includes CD38-GEAR-NK, a Vy-Gen drug formulated to combat CD38-positive cancers such as multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia. Complementing this, they offer CD38-Diagnostic, an in vitro screening tool designed to pinpoint which cancer patients would most likely benefit from specific anti-CD38 monoclonal antibody therapies. Beyond their core oncology focus, Coeptis has forged alliances, notably with Statera BioPharma for the development and market launch of STAT-201, intended for Crohn's disease. They also hold joint development and ownership rights for CPT60621, a potential treatment for Parkinson's Disease, through a collaboration with Vici Health Sciences, LLC. Established in 2017, Coeptis Therapeutics, Inc. is headquartered in Wexford, Pennsylvania.